Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM).
James MG Larkin, Karl D Lewis, Antoni Ribas, Keith Flaherty, Paolo Antonio Ascierto, Brigitte Dréno, Edward Francis Mckenna, Qian Zhu, Yong Mun, Axel Hauschild, Grant A McArthur
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2017
9556 Background: Treatment of BRAFV600-mutated mm with V and C+V has clinical benefit. Prior analyses established PFS/OS prognostic models in pts with mm based on clinical variables. This exploratory analysis evaluated the impact of immune and cell cycle gene signatures (GS) from baseline mm (Wongchenko et al, Pigment Cell Melanoma Res2015;28:822) on survival outcomes and associated prognostic models. Methods: Data from all eligible pts with GS data in the BRIM-2, -3, -7, and coBRIM studies were pooled for analysis. The independent effect of GS on PFS/OS outcomes was tested by multivariate Cox proportional hazards models. Recursive partitioning (RP) for censored response variables in a cond..View full abstract